Table 1. Inhibition of target agents in MCL cell lines.
Drug | IC50 | |||
---|---|---|---|---|
Jeko1 | Mino | Jeko1/BTZ | Mino/BTZ | |
Doxorubicin (μM) | 0.703 | 0.215 | 0.63 | 0.21 |
Vincristine (nM) | 0.638 | 0.631 | 0.47 | 0.43 |
PP2 (μM) | 43.516 | 37.742 | 15.947 | 8.745 |
LY294002 (μM) | 15.342 | 17.854 | 6.743 | 8.962 |
Rapamycin (μM) | >5 | >5 | 0.086 | 0.103 |
The IC50 value of various anti-cancer agents (BTZ, Doxorubicin, Vincristine, PP2, LY294002, and Rapamycin) for 72 hr treatment of Jeko1, Mino, and BTZ-resistant cells was determined using the MTT assay.